By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


SAGE Therapeutics 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression 1/12/2015 6:48:49 AM
SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus 1/9/2015 7:44:16 AM
SAGE Therapeutics To Present At 33rd Annual J.P. Morgan Healthcare Conference 1/5/2015 7:27:57 AM
SAGE Therapeutics Added To NASDAQ Biotechnology Index 12/17/2014 7:43:26 AM
SAGE Therapeutics Reports Third Quarter 2014 Results 11/11/2014 8:47:19 AM
SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus 11/10/2014 6:45:17 AM
MA Startup SAGE Therapeutics' Drug For Rare Epilepsy Shows Promise In Small Study 11/10/2014 6:44:06 AM
SAGE Therapeutics Announces Six Scientific Presentations At Neuroscience 2014, The Society For Neuroscience's 44th Annual Meeting 11/7/2014 12:12:19 PM
SAGE Therapeutics To Present At Credit Suisse 23rd Annual Healthcare Conference 11/5/2014 10:11:40 AM
SAGE Therapeutics Release: First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology 11/3/2014 8:31:38 AM